CTI profits fall short, exec departs

Article

Fourth quarter and year-end financial results for PET equipment maker CTI Molecular Imaging will not meet expectations. The company issued a profit warning Oct. 2, noting that earnings per share will range from 11¢ to 13¢ for the fourth quarter and 44¢

Fourth quarter and year-end financial results for PET equipment maker CTI Molecular Imaging will not meet expectations. The company issued a profit warning Oct. 2, noting that earnings per share will range from 11¢ to 13¢ for the fourth quarter and 44¢ to 46¢ for the full fiscal year. These are substantially lower than analysts' expectations of 20¢ for the quarter and 53¢ for the year. Costs associated with the acquisition of Mirada Solutions and, particularly, a shortfall in the number of scanner shipments-60 rather than the expected 66-were the principal causes, according to company officials. The deficit in shipments was due in part to delays imposed by the bankruptcy of DVI, the financial services firm that had helped fund the acquisition of scanners by CTI customers. Softening prices for PET equipment, due to increasingly aggressive competition, also affected earnings negatively.

One day prior to the profit warning, Terry D. Douglass, Ph.D., stepped down as president and CEO of the company. He was replaced by Ronald Nutt, Ph.D., CTI cofounder and current president of CPS Innovations, a joint venture between CTI and Siemens. Nutt directed CTI's scanner research and development efforts during most of the company's 20-year history. Douglass will continue to set the strategic direction of the company as chairman of the board.

Newsletter

Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.

Recent Videos
SNMMI: Emerging PET Insights on Neuroinflammation with Progressive Apraxia of Speech (PAOS) and Parkinson-Plus Syndrome
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
Related Content
© 2025 MJH Life Sciences

All rights reserved.